CMU Health offers transcranial magnetic stimulation for individuals with treatment-resistant depression. TMS is a non-invasive therapy that uses electromagnetic pulses to induce electrical activity in those parts of the brain that are underactive in depressed patients. The magnetic coils are placed against the patient’s head during a session. 

How effective is TMS therapy?

Effectiveness rates for TMS are estimated to be up to 62% for remission and up to 83% for reduction in symptoms by at least 50% for those who fully complete a course of TMS (Sackeim, et al., 2020). Medication treatment, generally estimated from the STAR-D trial, is up to 53% for reduction in symptoms by at least 50% and with full remission only seen in 40% of patients after two medication trials (Gaynes, et al., 2009).

Am I a candidate for TMS therapy?

We currently offer TMS to adult patients (ages 18 and up) who have not responded to standard treatments for major depression. These people have what is called treatment-resistant depression. If you are interested in TMS, you can meet with one of our clinicians to carefully review your medical history, current symptoms, and past treatments.

To be eligible for TMS treatment, you must not have:

  • Epilepsy or another seizure disorder.
  • Any metal implants in the skull.

How many TMS treatment sessions do you need?

The first session for treatment is 60 minutes, with subsequent treatment sessions between 20 to 30 minutes.

Most people start to feel better after 10 to 15 treatment sessions, which is equal to about two to three weeks of treatment. 

Key points about TMS therapy

  • Non-invasive, no anesthesia
  • FDA approved for treatment of major depression and obsessive compulsive disorder
  • Free from common antidepressant drug side effects such as weight gain and sexual dysfunction
  • Outpatient procedure

Clinicians to oversee the TMS clinic

Biography

Dr. Mohammad Jafferany is a Professor of Psychodermatology, Psychiatry, and Behavioral Sciences at Covenant HealthCare College of Medicine at Central Michigan University. With dual training in Dermatology and Psychiatry, he brings a unique interdisciplinary perspective to the field of psychocutaneous medicine. He currently serves as President of the Association for Psychocutaneous Medicine of North America (APMNA).

Dr. Jafferany has authored over 210 peer-reviewed articles and scholarly publications on a wide range of topics within psychodermatology. He has also edited and authored 12 influential books, including Pediatric Psychodermatology, Geriatric Psychodermatology, Stress and Skin, Trichotillomania, Essentials of Psychodermatology, Psychotrichology, and the Handbook of Psychodermatology. Several of these works have been translated into Russian, Ukrainian, Chinese, and Turkish languages, reflecting their global relevance.

A frequent speaker and educator, Dr. Jafferany has conducted international psychodermatology workshops and master courses around the world. He has several interviews in newspapers and magazines regarding skin-brain axis and mind-skin connection. He currently holds the position of Chairperson for World Psychodermatology Day, underscoring his ongoing dedication to advancing the fields of education, research, and clinical practice within psychodermatology. Additionally, he serves as a member of the Board of Directors for the International Society of Dermatology, further contributing to the global advancement of psychodermatological science.